Search tips
Search criteria 


Logo of clintransmedSpringerOpen.comSubmit OnlineRegisterThis journalThis article
Clin Transl Med. 2017; 6: 14.
Published online 2017 April 12. doi:  10.1186/s40169-017-0144-7
PMCID: PMC5389954

Thermodynamics in cancers: opposing interactions between PPAR gamma and the canonical WNT/beta-catenin pathway


Cancer cells are the site of numerous metabolic and thermodynamic abnormalities. We focus this review on the interactions between the canonical WNT/beta-catenin pathway and peroxisome proliferator-activated receptor gamma (PPAR gamma) in cancers and their implications from an energetic and metabolic point of view. In numerous tissues, PPAR gamma activation induces inhibition of beta-catenin pathway, while the activation of the canonical WNT/beta-catenin pathway inactivates PPAR gamma. In most cancers but not all, PPAR gamma is downregulated while the WNT/beta-catenin pathway is upregulated. In cancer cells, upregulation of the WNT/beta-catenin signaling induces dramatic changes in key metabolic enzymes that modify their thermodynamic behavior. This leads to activation of pyruvate dehydrogenase kinase1 (PDK-1) and monocarboxylate lactate transporter. Consequently, phosphorylation of PDK-1 inhibits the pyruvate dehydrogenase complex (PDH). Thus, a large part of pyruvate cannot be converted into acetyl-coenzyme A (acetyl-CoA) in mitochondria and only a part of acetyl-CoA can enter the tricarboxylic acid cycle. This leads to aerobic glycolysis in spite of the availability of oxygen. This phenomenon is referred to as the Warburg effect. Cytoplasmic pyruvate is converted into lactate. The WNT/beta-catenin pathway induces the transcription of genes involved in cell proliferation, i.e., MYC and CYCLIN D1. This ultimately promotes the nucleotide, protein and lipid synthesis necessary for cell growth and multiplication. In cancer, activation of the PI3K-AKT pathway induces an increase of the aerobic glycolysis. Moreover, prostaglandin E2 by activating the canonical WNT pathway plays also a role in cancer. In addition in many cancer cells, PPAR gamma is downregulated. Moreover, PPAR gamma contributes to regulate some key circadian genes. In cancers, abnormalities in the regulation of circadian rhythms (CRs) are observed. CRs are dissipative structures which play a key-role in far-from-equilibrium thermodynamics. In cancers, metabolism, thermodynamics and CRs are intimately interrelated.

Keywords: PPAR gamma, WNT/beta-catenin, Cancer, Circadian rhythms, Pyruvate dehydrogenase kinase, Pyruvate dehydrogenase complex, Aerobic glycolysis, Warburg effect, PI3 K-AKT pathway, Dissipative structures


Schrödinger in his famous book “What is life” [1] provided us a new understanding of the thermodynamics in living systems. By applying this to the thermodynamics of physical, chemical and biological far-from-equilibrium systems, Prigogine and his colleagues opened new avenues for the exploration of dissipative structures which occupy a major place in the living world [2, 3]. Cancer is an exergonic process in which heat flows from the tumor to its surroundings [4]. The entropy production rate is increased in cancer cells and is characteristic of irreversible processes driven by changes in heat production, Gibbs energy, intracellular acidity, ionic conductance, membrane potential gradient [5]. Numerous cellular mechanisms can induce and develop carcinogenic processes. In most cancers, the WNT/beta-catenin pathway is upregulated while peroxisome proliferator-activated receptor gamma (PPAR gamma) is downregulated. This profile has been observed in several diseases [6] such as cancers [7, 8], type 2 diabetes [9], and certain neurodegenerative diseases (amyotrophic lateral sclerosis [10], Huntington’s disease [11], multiple sclerosis [12, 13] and Friedreich’s ataxia [14]). The opposite profile has been reported in arrhythmogenic right ventricular cardiomyopathy (ARVC) [15, 16], osteoporosis [1719], and certain neurodegenerative diseases (Alzheimer’s disease [20], Parkinson’s disease [21], bipolar disorder [22, 23] and schizophrenia [24]). From a thermodynamic viewpoint and among numerous cellular processes involved in cancers, two major phenomena play a key role, i.e., aerobic glycolysis or the Warburg effect and disruption of circadian rhythms (CRs). The thermodynamic dysregulation induced by these two processes is consubstantial with metabolic abnormalities commonly found in cancers. PPAR dysfunction influences statistical mechanics by modifying thermodynamic force, thermodynamic flow, and rate of entropy production [5, 25]. We focus our review on the opposing interactions observed in cancers between the canonical WNT/beta-catenin pathway and PPAR gamma and their metabolic and energetic implications.

Canonical WNT/beta-catenin pathway

The canonical WNT/beta-catenin pathway plays an important role in metabolism, embryonic development, cell fate, and epithelial-mesenchymal transition (EMT) [ 26 ]. The canonical WNT activity is reflected by elevated levels of beta-catenin in the nucleus and/or cytoplasm, which can be detected by means of immunohistochemical staining, Western blotting and semiquantitative RT-PCR [27]. Its dysfunction is involved in numerous diseases, particularly in cancers [2831]. The transcription factor beta-catenin/T-cell factor/lymphoid enhancer factor (TCF/LEF) represents the key effector of the canonical WNT pathway (Figs. 1, ,2).2). The destruction complex consists of AXIN, tumor suppressor adenomatous polyposis coli (APC), and glycogen synthase kinase-3 (GSK-3beta). The destruction complex exerts a tight control on the beta-catenin signaling. In the absence of WNT ligands (“off state”), the destruction complex phosphorylates beta-catenin which is then degraded in the proteasome. In the presence of WNT ligands (“on state”), the WNT receptor interacts with Frizzled (FZL) and LDL receptor-related protein 5/6 (LRP5/6). WNT receptor is associated with Dishevelled (DSH). This triggers the disruption of the destruction complex and prevents degradation of beta-catenin in the proteasome. Beta-catenin then translocates to the nucleus and interacts with TCF/LEF. This leads to the stimulation of the beta-catenin target genes (pyruvate dehydrogenase kinase (PDK), monocarboxylate lactate transporter-1 (MTC-1), MYC, CYCLIN D1, cyclooxygenase-2 (COX-2), AXIN) [3235] (Fig. 1).

Fig. 1
Schema of interactions between the canonical WNT/beta-catenin pathway and PPAR gamma under aerobic glycolysis conditions in cancer. In the absence of the WNT ligands (“off state”), cytosolic beta-catenin is phosphorylated by GSK-3 beta. ...
Fig. 2
Synthetic diagram of opposing effects of PPAR gamma and canonical WNT/beta-catenin signaling in cancer. Green arrow activation; red arrow inhibition; A-CoA acetyl-CoA, GSK-3beta glycogen synthase kinase-3beta, IC lactate intracellular lactate, EC lactate ...

PPAR gamma

Peroxisome proliferator-activated receptor gamma is a ligand-activated transcriptional factor that belongs to the nuclear hormone receptor superfamily [36]. It heterodimerizes with the retinoid X receptor. PPAR gamma is expressed in numerous cell types, such as adipose tissues, muscles, brain, and immune cells. PPAR gamma activates the expression of many genes and regulates glucose homeostasis, insulin sensitivity, lipid metabolism, immune responses, cell fate and inflammation [3739]. PPAR gamma agonists thiazolidinediones (TZDs) improve insulin sensitivity in peripheral tissues [40] and ameliorate glucose tolerance and insulin sensitivity in type 2 diabetic patients [41]. TZDs act on the promoters of glucose transporter (GLUT-2) and glucokinase (GK) in pancreatic beta-cells and liver. Abnormalities of PPAR gamma are observed in several pathological states such as cancers, diabetes, obesity, and atherosclerosis. Some TZDs have been used for treating type 2 diabetes. PPAR gamma also plays an important role in regulating cardiovascular rhythms by controlling circadian variations of blood pressure and heart rate through BMAL1 [42, 43]. However, numerous side effects induced by TZD have been reported [44].

Opposing effects of the canonical WNT/beta-catenin pathway and PPAR gamma

The link between the WNT/beta-catenin pathway and PPAR gamma involves the TCF/LEF beta-catenin-binding domain and a catenin binding domain within PPAR gamma. In numerous mammalian cells, PPAR gamma and WNT/beta-catenin signaling behave in an opposite manner [4550]. In some diseases, although the WNT/beta-catenin pathway is downregulated, PPAR gamma appears to be upregulated and vice versa (see: “Introduction”) [6]. In several cellular systems, beta-catenin is inhibited by PPAR gamma agonists [45, 47, 48, 51]. It has also been observed that inhibition of the WNT/beta-catenin pathway induces activation of PPAR gamma [15].

Aerobic glycolysis in cancer cells: role of the canonical WNT signaling

The role of the WNT/beta-catenin signaling in cancer development, especially in colorectal cancer, is now better understood [52, 53]. Upregulation of the WNT/beta-catenin pathway via TCF/LEF leads to cell proliferation, EMT, migration and angiogenesis [5456]. In cancer cells, overactivation of the WNT/beta-catenin pathway induces aerobic glycolysis. This allows glucose utilization for cell proliferation [35]. Thus in a large part, glucose supply is fermented in lactate regardless of oxygen availability. This phenomenon is referred to as aerobic glycolysis or the Warburg effect [57].

In cancer, the behavior of two key enzymes involved in glucose metabolism is modified leading to the Warburg effect. Activation of PDK-1 is required for the Warburg aerobic glycolysis. Upregulation of WNT/beta-catenin signaling activates both PDK-1 and MCT-1 [35, 58]. PDK-1, a major regulator of glucose metabolism, phosphorylates the pyruvate dehydrogenase complex (PDH) which is inhibited and largely prevents the conversion of pyruvate into acetyl-CoA in mitochondria [59]. In colon cancer, PDK-1 is upregulated [35, 60], so that the conversion of pyruvate into acetyl-CoA in mitochondria is diminished with a consequent reduction of acetyl-CoA entering the tricarboxylic acid (TCA) cycle. This induces aerobic glycolysis in spite of the availability of oxygen. PDK-1 has also been observed to be upregulated in several other cancers [61, 62]. Cytosolic pyruvate is converted into lactate through activation of lactic dehydrogenase-A (LDH-A). Upregulation of both LDH-A and MCT-1 results in pyruvate being diverted towards the formation of lactate and the secretion of the latter outside of the cell, which favors angiogenesis [63] and ultimately leads to anabolic production of biomass i.e., nucleotide synthesis [64, 65]. The Warburg effect partly shunts the TCA cycle leading to aerobic glycolysis which is less efficient in terms of ATP production. The most cost effective way producing ATP is via glucose oxidation (ATP/O2 = 6.4), since the pathway via free fatty acid beta-oxidation is less efficient (ATP/O2 = 5.6). This takes about 11% more O2 to produce the same amount of ATP from fatty acids as it does from glucose. Moreover, PDK-1 and 2 enhance angiogenesis [66, 67]. Blocking WNT reduces the PDK-1 level via the transcription regulation and reduces in vivo tumor growth [35]. Conversely, PPAR gamma activation selectively decreases PDK mRNA [68]. PDKs allow metabolic flexibility [69] and are transcriptionally regulated by insulin, glucocorticoids, thyroid hormone and fatty acids [70]. Several diseases presenting PDK abnormalities are often associated with type 2 diabetes, obesity, metabolic disorders, cardiomyopathies, neuropathies and cancers.

In colon cancer, activation of WNT/beta-catenin signaling decreases the oxidative metabolism in the TCA cycle and promotes cell proliferation [35]. In addition, the WNT/beta-catenin pathway induces the transcription of genes involved in cell proliferation, particularly CYCLIN D1 and MYC operating through the G1 phase [7174]. MYC activates aerobic glycolysis and glutaminolysis and favors nucleotide synthesis [75, 76]. MYC also activates LDH-A, induces glutamine uptake into the cell and mitochondria, and stimulates aspartate synthesis which favors nucleotide synthesis [75] (Fig. 1). Moreover, MYC increases the hypoxia-inducible factor -1alpha (HIF1A) which controls PDK-1 [77]. Part of the pyruvate is converted into acetyl-CoA which in turn enters the TCA cycle and is converted into citrate. This promotes protein and lipid synthesis. Cellular accumulation of metabolic intermediates (aspartate, serine, glycine, and ribose) allows de novo nucleotide synthesis, which contributes to growth and proliferation.

Phosphofructokinase (PFK), an allosteric enzyme, is responsible for glycolytic oscillations. PFK can lead to instabilities beyond which a new state can be organized in time and in space [78]. A positive feedback is responsible for periodic behavior. These far-from-equilibrium oscillatory mechanisms come within the field of dissipative structures initially described by Illia Prigogine [79]. Elevated PFK-1 activity is characteristic of cancer cells and is induced in response to oncogenes [80].

Cancer cells are characterized by increased glucose consumption. High serum glucose levels may modulate cancer-related processes. Glucose itself can directly impact the canonical WNT pathway [81]. High glucose level enhances the nuclear translocation of beta-catenin in response to WNT activation. In cancer cells, glucose-induced beta-catenin acetylation favors the WNT pathway.

Aerobic glycolysis and vitamin C

It has been recently described a novel antitumoral mechanism of vitamin C [82]. Mutation of the proto-oncogene KRAS is often present in colon and pancreatic cancer. In KRAS mutant colorectal cancer, this mechanism involves the Warburg metabolic disruption. In the absence of vitamin C, pyruvate kinase PKM2 is phosphorylated, then translocates to the nucleus and binds the beta-catenin/TCF/LEF transcriptional factor. This promotes the MYC transcription which in turn enhances GLUT-1 and Polypyrimidine Tract Binding Protein (PTB) expression. In the presence of vitamin C which enters into the cell via GLUT-1, RAS is detached from the cell membrane which blocks the PKM2 phosphorylation. This induces downregulation of GLUT-1 and PKM2 expression via disruption of the beta-catenin/TEF/LEF transcriptional complex. This leads to downregulation of MYC and inhibition of the Warburg pathway. Thus, vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer.

Thermodynamics and lawless-disorderly cancer growth

From a thermodynamic viewpoint, the lawless-disorderly cancer growth and the orderly fetal growth share some similar features [83]. Hypoxic conditions reported in cancer cells for their growth requirements resemble to those observed during normal fetal growth, which requires a relatively low oxygen tension. For both cancerous and fetal growth, low energy requirements are linked to the tumorigenic arm of acute inflammation [83], as in wound healing. Moreover, the production of lactate under aerobic glycolysis conditions is characteristic of the human placenta [84], a tissue in which the population of contractile myofibroblasts is important [85]. In cancer (mammary carcinoma, epithelial cells in cancerous mammary glands), fibrotic lesions (Dupuytrens nodules, hypertrophic scars) [86], and normal placental stem villi [87], the main myosin molecular motor in myofibroblasts is the non muscle myosin (NMM). Kinetics of contractile NMM crossbridges are dramatically slow [88] and their entropy production rate is extremely low [89]. The presence of numerous myofibroblasts is associated with the aerobic glycolysis metabolism. In epithelial cancers, myofibroblasts represent a significant part of the stroma reaction. Myofibroblasts, epithelial cells, and connective tissue cells participate to cancer invasion, with loss of epithelial characteristics and acquisition of mesenchymal properties. This refers to as EMT [26] which greatly influences the invasive carcinoma progression and in which the canonical WNT pathway plays a key role. WNT3a favors myofibroblast differentiation by upregulating the transforming growth factor (TGF-beta1). This occurs through SMAD2 in a beta-catenin-dependent manner [90]. Importantly, it has been recently demonstrated that aerobic glycolysis is induced in response to TGF-beta1 [91].

Activation of WNT/beta-catenin pathway and inactivation of PPAR gamma in cancers

WNT/beta-catenin signaling has been found to be activated in cancers [92, 93]. WNT1 was first discovered as a proto-oncogene in a breast cancer mouse model. Increased expression of beta-catenin may be due to factors such as mutations in beta-catenin, abnormalities in the beta-catenin destruction complex, mutations in APC, overexpression of WNT ligands, and loss of inhibition or decreased activity of regulatory pathways. Alterations in gene expression of CTNNB1 which encodes beta-catenin, have been reported in numerous cancers such as breast colorectal, melanoma, prostate and lung tumors. WNT 1, WNT2 and WNT7A ligand-proteins are overexpressed in glioblastoma, esophageal cancer and ovarian cancer respectively. Proteins of the TCF/LEF family and WNT5A may also induce cancer. Repression of WNT/beta-catenin signaling can prevent EMT and inhibit metastasis. Mutations of the WNT pathway components are associated with many cancers, particularly with colorectal cancer. APC deficiency and beta-catenin mutations upregulate the WNT/beta-catenin pathway and prevent beta-catenin degradation. This leads to excessive stem cell renewal and cell proliferation that predisposes to tumor genesis particularly for colorectal cancer [94]. Nuclear accumulation of beta-catenin drives cancer cell proliferation. In colon cancer, beta-catenin-TCF/LEF signaling is activated [95], and activation of the WNT pathway via APC gene mutations favors cell proliferation [96]. Mutations in PPAR gamma are linked with human colon cancer [97].

Several studies have presented evidence for a protective role of PPAR gamma against cancer. In colon cancer, PPAR gamma downregulates the oncogene beta-catenin and suppresses cell proliferation [98]. In contrast, other studies have implicated PPAR gamma in the promotion and development of cancer [8]. Thus, PPAR gamma activation by specific agonists can induce growth inhibition, apoptosis and differentiation of numerous tumor cells. On the contrary, overexpression of PPAR gamma has been reported in tumors of colon, breast, prostate, stomach, salivary gland, cervix, ovary, bladder, lung, testes and the neural crest element of sympathetic nervous system [7]. The biological significance of PPAR gamma in cancer remains controversial. Activation of PPAR gamma can induce either tumor suppressive or promoting responses. On the one hand, PPAR gamma can act as a tumor inhibitor in colon cancer [99105], in breast cancer [106110], in urological cancer [110115], in lung cancer [116118], and in gastric cancer [119122]. On the other hand, PPAR gamma can act as a tumor promotor in colon cancer [123126], in breast cancer [127132], and in urological cancer [133135]. There is no clear unifying accepted mechanism explaining these contradictory evidences concerning either the protective role of PPAR gamma or their role on promotion/development of cancer. This might be partly explained by cell type-specific effects, organ-specific effects, receptor-independent effects according to the PPAR gamma agonist used. This might also be due to specific pharmacokinetic properties of PPAR gamma ligands or the stage of cancer development at which the PPAR gamma ligand is administered [8]. These arguments are hypotheses, and for the time being, no universal mechanism is able to explain the contradictory effects of PPAR gamma ligands on cancers.

Role of PI3K-AKT pathway in aerobic glycolysis and cancers

Hyperactivation of phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT) pathway is associated with an increased rate of glucose metabolism in tumor cells [136]. AKT signaling directly acts on aerobic glycolysis in cancer cells. AKT regulates the localization of GLUT1 in the plasma membrane and hexokinase expression. It also activates phosphofructokinase-1 (PFK-1) which directly phosphorylates PFK-2. This leads to produce fructose-2.6-bisphosphate, an activator of PFK-1. AKT activation causes an increase in aerobic glycolysis or Warburg effect in cancer. PI3K-AKT pathway promotes cell survival, cell growth, cell proliferation, cell migration and angiogenesis in response to extracellular signals including hormones and growth factors. This pathway is stimulated by the binding of extracellular ligands to a receptor tyrosine kinase (RTK) located in the plasma membrane (Fig. 1). This signaling is upregulated in certain cancers. Through phosphorylation of GSK-3beta, PI3 K-AKT favors the G1 phase of the cell cycle. GSK-3beta phosphorylation decreases the degradation of beta-catenin in the proteasome. Thus, TCF/LEF transcription factor is activated which in turn favors transcription of the target gene CYCLIN D1 [137]. Consequently, by decreasing the GSK-3beta activity, AKT pathway behaves similarly to the WNT pathway. Aberrant activation of PI3K-AKT is often associated with cancers, including glioblastomas, ovarian, pancreatic and breast cancers [138]. AKT mRNA is increased in breast and prostate cancer. PI3K-AKT contributes to angiogenesis by acting on the vascular endothelial growth factor in endothelial cells and on the endothelial nitric oxide synthase. This activates vasodilation and vascular remodeling [139]. Moreover, the PI3K-AKT pathway increases the hypoxia-inducible transcription factor [140].

The phosphatase and tensin homologue (PTEN) represents the main brake of the PI 3′-OH kinase (PIK3)-AKT pathway [141]. PI3K generate phosphatidylinositol-3,4,5-triphosphate (PIP3) from PIP2. AKT is activated by PIP3. PTEN is a PIP3-phosphatase and its activity is opposed to that of PI3K. PI3K-AKT signaling is a major pathway which is activated in cancer. PTEN appears to be relevant against cancer progression and represents a target for somatic cancer inactivation. In some cancers (endometrial, breast, and colorectal cancers), PI3K and PTEN mutations coexist. PTEM also induces a decrease in cancer cell proliferation due to cell cycle arrest in the G1 phase.

Prostaglandins, WNT and PPAR gamma

Several studies have established the role of prostaglandin E2 (PGE2) by activating the WNT/beta-catenin pathway. The link between PGE2 and the canonical WNT pathway suggests that chronic inflammation induced by a prolonged increase of PGE2 could lead to activation of WNT signaling resulting in cell proliferation and cancer. PGE2 enhances the beta-catenin-dependent transcription [142, 143]. PGE2 promotes colon cancer cell growth through the beta-catenin pathway. Thus, blockage of WNT/beta-catenin signaling can be of interest for cancer treatment. In treatment of colorectal cancer, nonsteroidal anti-inflammatory drugs (NSAIDs) induce beneficial effects [144], partly due to their interaction with the beta-catenin pathway and their inhibition of the PGE2 synthesis. PGE2 modulates the WNT activity in hematopoietic stem cell (HSC) in zebrafish. Inhibition of PGE2 synthesis blocks alterations in HSC induced by WNT. PGE2 modifies the WNT signaling cascade at the level of beta-catenin degradation through the cAMP/PKA pathway. WNT activation in stem cells requires PGE2 [145]. Dimethyl-prostaglandin E2 increases HSC in vivo. In addition, dimethyl-prostaglandin E2 leads to the formation of components of the WNT pathway [146]. WNT signaling upregulates interleukin (IL)-7R and IL-2Rbeta. In neuroectodermal (NE-4C) stem cells, PGE2 interacts with the canonical WNT signaling through PKA and PI3K [147]. In WNT-induced cells, beta-catenin is increased and the WNT-target genes (Ctnnb1, Ptgs2, Ccnd1, Mmp9) are significantly upregulated after PGE2 use. PPAR gamma and proinflammatory enzyme pathways are interrelated. Decreased expression of PPAR gamma and high levels of COX-2 have been reported in many cancers [148]. TZDs decrease COX-2, inhibit growth of non-small-cell lung cancer cells in vitro, and block tumor development. TZDs diminish COX-2 and PGE2 through PPAR gamma. The PPAR gamma activator 15dPGJ2 plays an anti-inflammatory role in a PPAR gamma-dependent manner, decreasing COX-2, PGE2 and iNos expression [149].

Circadian rhythms (CRs), cancers, metabolism and thermodynamics

CRs can be defined as endogenous, entrainable free-running periods that last approximately 24 h. CRs are far-from-equilibrium dissipative structures and are due to a negative feedback produced by a protein on the expression of its own gene [150152]. They operate in far-from-equilibrium manner if affinity of the studied system is [dbl greater-than sign]RT (R is the universal gas constant and T is the absolute temperature), and generate order spontaneously by exchanging energy with their external environment [2, 153]. In mammals, CRs involve several major critical transcription factors such as circadian locomotor output cycles kaput (CLOCK), brain and muscle aryl-hydrocarbon receptor nuclear translocator-like1 (BMAL1), period 1 (PER1), period 2 (PER2), and period 3 (PER3) [154, 155]. Transcription/translation autoregulatory feedback loops with both activating and inhibiting pathways are involved in CRs [156, 157].

Circadian rhythms govern numerous physiological and metabolic functions [158]. Thus, CRs are observed in sleep-awake and feeding patterns, energy metabolism, body temperature, hormone secretion, heart rate and blood pressure. Following epidemioloigical and genetic probes, it has been suggested that disruption of CRs may be directly linked to cancer, leading to aberrant cellular proliferation [159]. Since numerous connections between the circadian clock and cellular metabolism have been reported, it is thougth that the abnormal metabolism observed in cancer may be a consequence of disrupted CRs. CRs within the cell regulate the timing of many important life cycles [160]. The phase diffusion constant depends on the free-energy dissipation per period. Oscillations are driven by multiple irreversible cycles that hydrolyze fuel molecules such as ATP. The free energy consumed per period is proportional to the number of phase coherent periods. A decreased BMAL1 function modifies the behavior of genes involved in the canonical WNT pathway [161]. Beta-catenin induces PER2 degradation altering circadian clock gene in intestinal mucosa of ApcMin/+ mice [162]. A deceased expression level of PER1 and/or PER2 has been reported in numerous cancers: breast cancer [163], prostate cancer [164], pancreatic cancer [165], colorectal cancer [166], chronic myeloid leukemia [167], and glioma [168, 169].

Peroxisome proliferator-activated receptors interferes with the mammalian clock and energy metabolism [170]. PPARs are rhythmically expressed in mammalian tissues [171] and directly interact with the core clock genes. PPAR gamma exhibits variations in diurnal expression in mouse fat, liver and blood vessels [42]. Deletion of PPAR gamma in mouse impairs diurnal rhythms [172]. PPAR gamma plays an important role in the coordinated control of circadian clocks, metabolism and cardiac performance. PGC-1 alpha, a transcriptional co-activator that regulates energy metabolism, is rhythmically expressed in the liver and skeletal muscle of mice. PGC-1 alpha upregulates the expression of the clock genes BMAL1 and Rev-erb alpha. Mice lacking PGC-1 alpha show changes in CRs and metabolism [173]. PGC-1 alpha acts as a stress sensor in cancer cells. In maintaining metabolic homeostasis, PGC-1 alpha favors cancer cell survival [174]. PGC-1 alpha interfers in a very complex manner with nuclear receptors such as Rev-erb, ROR, PPARs [175]. PPAR alpha and gamma up-regulate the expression of Rev-erb alpha and BMAL1 by binding to their promotors. PGC-1 potentiates ROR alpha transcriptional activity and enhances both Rev-erb alpha and BMAL1 transcription. Moreover after serum shock, GSK-3beta-mediated stabilization of Rev-erb alpha plays a key role to initiate, maintain and synchronize CRs.


Cancers exhibit thermodynamic and metabolic alterations and abnormal CRs. In many cancers but not all, the canonical WNT/beta-catenin pathway is upregulated, while PPAR gamma is downregulated, the two systems behaving in an opposite manner. Overactivation of the WNT pathway results in cell proliferation due to the activation of certain target genes of beta-catenin, such as MYC and CYCLIN D1. This promotes protein synthesis and angiogenesis. PDK and MCT-1 are also target genes of beta-catenin, explaining the significant decrease in the transformation of pyruvate into acetyl-CoA in mitochondria and the formation of intracellular lactate, which will be extruded out of the cell. This is referred to as aerobic glycolysis or the Warburg phenomenon. The expression of PPAR gamma is decreased due to the overactivation of WNT/beta-catenin signaling. Circadian rhythms, dissipative structures which are governed by the laws of far-from-equilibrium thermodynanics are disrupted in cancers. They are influenced by both the WNT/beta-catenin pathway and PPAR gamma. Changes in thermodynamics, metabolism and circadian rhythms are tightly linked in cancers.

Authors’ contributions

YL, VC, AV and J-LH have contributed equally to this review. All authors read and approved the final manuscript.


We would like to thank Dr. Christophe Locher, President of the “Fédération de la Recherche Clinique du Grand Hôpital de l’Est Francilien”, and Mr. Vincent Gobert, Administrative Manager of the Clinical Research Center, Meaux Hospital, Meaux, France, for their valuable support in making the necessary research facilities available for this study. The manuscript has been revised by Brian Keogh, Ph.D.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


acetyl-coenzyme A
adenomatous polyposis coli
arrhythmogenic right ventricular dysplasia/cardiomyopathy
brain and muscle aryl-hydrocarbon receptor nuclear translocator-like1
circadian locomotor output cycles kaput
epithelial-mesenchymal transition
glucose transporter
glycogen synthase kinase-3beta
hematopoietic stem cell
lactate dehydrogenase
low-density lipoprotein receptor-related protein 5/6
monocarboxylate lactate transporter-1
nonsteroidal anti-inflammatory drug
peroxisome proliferator-activated receptor
PGC-1 alpha
peroxisome proliferator-activated receptor-gamma coactivator-1 alpha
phosphatidylinositol 3-kinase-protein kinase B
prostaglandin E2
pyruvate dehydrogenase complex
pyruvate dehydrogenase kinase
receptor tyrosine kinase
T cell factor factor/lymphoid enhancer factor
transforming growth factor
tricarboxylic acid

Contributor Information

Yves Lecarpentier, moc.liamg@reitnepracel.c.sevy.

Victor Claes, eb.telracs@sealc.rotciv.

Alexandre Vallée, rf.oohay@xela_eellav.

Jean-Louis Hébert, moc.liamg@trebeh.l.naej.


1. Schrödinger E (1944) What is life?: Cambridge University Press, Cambridge
2. Prigogine I, Nicolis G, Babloyantz A. Nonequilibrium problems in biological phenomena. Ann NY Acad Sci. 1974;231:99–105. doi: 10.1111/j.1749-6632.1974.tb20557.x. [PubMed] [Cross Ref]
3. Prigogine I. Life and physics. New perspectives. Cell Biophys. 1986;9:217–224. doi: 10.1007/BF02797383. [PubMed] [Cross Ref]
4. Atkins PW. Physical chemistry. Oxford: Oxford University Press; 1990. pp. 1–1031.
5. Kondepudi D, Prigogine I. Modern thermodynamics from heat engines to dissipative structures. New York: Wiley; 1999. pp. 1–486.
6. Lecarpentier Y, Claes V, Duthoit G, Hebert JL. Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction. Front Physiol. 2014;5:429. doi: 10.3389/fphys.2014.00429. [PMC free article] [PubMed] [Cross Ref]
7. Krishnan A, Nair SA, Pillai MR. Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med. 2007;7:532–540. doi: 10.2174/156652407781695765. [PubMed] [Cross Ref]
8. Youssef J, Badr M. Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol. 2011;164:68–82. doi: 10.1111/j.1476-5381.2011.01383.x. [PMC free article] [PubMed] [Cross Ref]
9. Lecarpentier Y, Claes V, Vallee A, Hébert JL. Interactions between PPAR gamma and the canonical Wnt/beta-catenin pathway in type 2 diabetes and colon cancer. PPAR Res. 2017;5:1–9. doi: 10.1155/2017/5879090. [PMC free article] [PubMed] [Cross Ref]
10. Lecarpentier Y, Vallee A. Opposite interplay between PPAR gamma and canonical Wnt/Beta-catenin pathway in amyotrophic lateral sclerosis. Front Neurol. 2016;7:100. doi: 10.3389/fneur.2016.00100. [PMC free article] [PubMed] [Cross Ref]
11. Godin JD, Poizat G, Hickey MA, Maschat F, Humbert S. Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington’s disease. EMBO J. 2010;29:2433–2445. doi: 10.1038/emboj.2010.117. [PubMed] [Cross Ref]
12. Drew PD, Xu J, Racke MK. PPAR-gamma: therapeutic potential for multiple sclerosis. PPAR Res. 2008;2008:627463. doi: 10.1155/2008/627463. [PMC free article] [PubMed] [Cross Ref]
13. Yuan S, Shi Y, Tang SJ. Wnt signaling in the pathogenesis of multiple sclerosis-associated chronic pain. J Neuroimmune Pharmacol. 2012;7:904–913. doi: 10.1007/s11481-012-9370-3. [PubMed] [Cross Ref]
14. Coppola G, Marmolino D, Lu D, Wang Q, Cnop M, et al. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich’s ataxia. Hum Mol Genet. 2009;18:2452–2461. doi: 10.1093/hmg/ddp183. [PMC free article] [PubMed] [Cross Ref]
15. Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, et al. Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest. 2006;116:2012–2021. doi: 10.1172/JCI27751. [PMC free article] [PubMed] [Cross Ref]
16. Djouadi F, Lecarpentier Y, Hebert JL, Charron P, Bastin J, et al. A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Res. 2009;84:83–90. doi: 10.1093/cvr/cvp183. [PubMed] [Cross Ref]
17. Canalis E. Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol. 2013;9:575–583. doi: 10.1038/nrendo.2013.154. [PubMed] [Cross Ref]
18. Rawadi G, Roman-Roman S. Wnt signalling pathway: a new target for the treatment of osteoporosis. Expert Opin Ther Targets. 2005;9:1063–1077. doi: 10.1517/14728222.9.5.1063. [PubMed] [Cross Ref]
19. Korvala J, Juppner H, Makitie O, Sochett E, Schnabel D, et al. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med Genet. 2012;13:26. doi: 10.1186/1471-2350-13-26. [PMC free article] [PubMed] [Cross Ref]
20. Vallee A, Lecarpentier Y. Alzheimer disease: crosstalk between the canonical Wnt/beta-catenin pathway and PPARs alpha and gamma. Front Neurosci. 2016;10:459. doi: 10.3389/fnins.2016.00459. [PMC free article] [PubMed] [Cross Ref]
21. Berwick DC, Harvey K. The importance of Wnt signalling for neurodegeneration in Parkinson’s disease. Biochem Soc Trans. 2012;40:1123–1128. doi: 10.1042/BST20120122. [PubMed] [Cross Ref]
22. Gould TD, Manji HK. The Wnt signaling pathway in bipolar disorder. Neuroscientist. 2002;8:497–511. doi: 10.1177/107385802237176. [PubMed] [Cross Ref]
23. Valvezan AJ, Klein PS. GSK-3 and Wnt signaling in neurogenesis and bipolar disorder. Front Mol Neurosci. 2012;5:1. doi: 10.3389/fnmol.2012.00001. [PMC free article] [PubMed] [Cross Ref]
24. Panaccione I, Napoletano F, Forte AM, Kotzalidis GD, Del Casale A, et al. Neurodevelopment in schizophrenia: the role of the wnt pathways. Curr Neuropharmacol. 2013;11:535–558. doi: 10.2174/1570159X113119990037. [PMC free article] [PubMed] [Cross Ref]
25. Lecarpentier Y, Krokidis X, Martin P, Pineau T, Hebert JL, et al. Increased entropy production in diaphragm muscle of PPAR alpha knockout mice. J Theor Biol. 2008;250:92–102. doi: 10.1016/j.jtbi.2007.09.022. [PubMed] [Cross Ref]
26. Heuberger J, Birchmeier W. Interplay of cadherin-mediated cell adhesion and canonical wnt signaling. Cold Spring Harb Perspect Biol. 2010;2:a002915. doi: 10.1101/cshperspect.a002915. [PMC free article] [PubMed] [Cross Ref]
27. Igota S, Tosa M, Murakami M, Egawa S, Shimizu H, et al. Identification and characterization of Wnt signaling pathway in keloid pathogenesis. Int J Med Sci. 2013;10:344–354. doi: 10.7150/ijms.5349. [PMC free article] [PubMed] [Cross Ref]
28. Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science. 2002;296:1644–1646. doi: 10.1126/science.1071549. [PubMed] [Cross Ref]
29. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004;5:691–701. doi: 10.1038/nrg1427. [PubMed] [Cross Ref]
30. Nusse R. Wnt signaling in disease and in development. Cell Res. 2005;15:28–32. doi: 10.1038/ [PubMed] [Cross Ref]
31. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469–480. doi: 10.1016/j.cell.2006.10.018. [PubMed] [Cross Ref]
32. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509–1512. doi: 10.1126/science.281.5382.1509. [PubMed] [Cross Ref]
33. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D’Amico M, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 1999;96:5522–5527. doi: 10.1073/pnas.96.10.5522. [PubMed] [Cross Ref]
34. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 2009;10:468–477. doi: 10.1038/nrn2674. [PubMed] [Cross Ref]
35. Pate KT, Stringari C, Sprowl-Tanio S, Wang K, TeSlaa T, et al. Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer. EMBO J. 2014;33:1454–1473. [PubMed]
36. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011;2:236–240. doi: 10.4103/2231-4040.90879. [PMC free article] [PubMed] [Cross Ref]
37. Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun. 1996;224:431–437. doi: 10.1006/bbrc.1996.1044. [PubMed] [Cross Ref]
38. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, et al. The organization, promoter analysis, and expression of the human PPAR gamma gene. J Biol Chem. 1997;272:18779–18789. doi: 10.1074/jbc.272.30.18779. [PubMed] [Cross Ref]
39. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20:649–688. [PubMed]
40. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci. 2004;25:331–336. doi: 10.1016/ [PubMed] [Cross Ref]
41. Picard F, Auwerx J. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr. 2002;22:167–197. doi: 10.1146/annurev.nutr.22.010402.102808. [PubMed] [Cross Ref]
42. Wang N, Yang G, Jia Z, Zhang H, Aoyagi T, et al. Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1. Cell Metab. 2008;8:482–491. doi: 10.1016/j.cmet.2008.10.009. [PubMed] [Cross Ref]
43. Lecarpentier Y, Claes V, Hebert JL. PPARs, cardiovascular metabolism, and function: near- or far-from-equilibrium pathways. PPAR Res. 2010 [PMC free article] [PubMed]
44. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19:557–566. doi: 10.1038/nm.3159. [PMC free article] [PubMed] [Cross Ref]
45. Gerhold DL, Liu F, Jiang G, Li Z, Xu J, et al. Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrinology. 2002;143:2106–2118. [PubMed]
46. Girnun GD, Domann FE, Moore SA, Robbins ME. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol. 2002;16:2793–2801. doi: 10.1210/me.2002-0020. [PubMed] [Cross Ref]
47. Sharma C, Pradeep A, Wong L, Rana A, Rana B. Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J Biol Chem. 2004;279:35583–35594. doi: 10.1074/jbc.M403143200. [PubMed] [Cross Ref]
48. Takada I, Kouzmenko AP, Kato S. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol. 2009;5:442–447. doi: 10.1038/nrrheum.2009.137. [PubMed] [Cross Ref]
49. Lu D, Carson DA. Repression of beta-catenin signaling by PPAR gamma ligands. Eur J Pharmacol. 2010;636:198–202. doi: 10.1016/j.ejphar.2010.03.010. [PMC free article] [PubMed] [Cross Ref]
50. Liu J, Wang H, Zuo Y, Farmer SR. Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol Cell Biol. 2006;26:5827–5837. doi: 10.1128/MCB.00441-06. [PMC free article] [PubMed] [Cross Ref]
51. Moldes M, Zuo Y, Morrison RF, Silva D, Park BH, et al. Peroxisome-proliferator-activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis. Biochem J. 2003;376:607–613. doi: 10.1042/bj20030426. [PubMed] [Cross Ref]
52. Thompson CB. Wnt meets Warburg: another piece in the puzzle? EMBO J. 2014;33:1420–1422. [PubMed]
53. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2000;103:311–320. doi: 10.1016/S0092-8674(00)00122-7. [PubMed] [Cross Ref]
54. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal–epithelial transition, stem cells and beta-catenin. Cells Tissues Organs. 2005;179:56–65. doi: 10.1159/000084509. [PubMed] [Cross Ref]
55. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8:387–398. doi: 10.1038/nrc2389. [PubMed] [Cross Ref]
56. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149:1192–1205. doi: 10.1016/j.cell.2012.05.012. [PubMed] [Cross Ref]
57. Warburg O. On the origin of cancer cells. Science. 1956;123:309–314. doi: 10.1126/science.123.3191.309. [PubMed] [Cross Ref]
58. Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, et al. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 2008;452:139–146. doi: 10.1007/s00428-007-0558-5. [PubMed] [Cross Ref]
59. Roche TE, Baker JC, Yan X, Hiromasa Y, Gong X, et al. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog Nucleic Acid Res Mol Biol. 2001;70:33–75. doi: 10.1016/S0079-6603(01)70013-X. [PubMed] [Cross Ref]
60. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006;66:632–637. doi: 10.1158/0008-5472.CAN-05-3260. [PubMed] [Cross Ref]
61. Wigfield SM, Winter SC, Giatromanolaki A, Taylor J, Koukourakis ML, et al. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. Br J Cancer. 2008;98:1975–1984. doi: 10.1038/sj.bjc.6604356. [PMC free article] [PubMed] [Cross Ref]
62. Baumunk D, Reichelt U, Hildebrandt J, Krause H, Ebbing J, et al. Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC) World J Urol. 2013;31:1191–1196. doi: 10.1007/s00345-012-0874-5. [PubMed] [Cross Ref]
63. Hunt TK, Aslam RS, Beckert S, Wagner S, Ghani QP, et al. Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxid Redox Signal. 2007;9:1115–1124. doi: 10.1089/ars.2007.1674. [PMC free article] [PubMed] [Cross Ref]
64. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11–20. doi: 10.1016/j.cmet.2007.10.002. [PubMed] [Cross Ref]
65. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–1033. doi: 10.1126/science.1160809. [PMC free article] [PubMed] [Cross Ref]
66. McFate T, Mohyeldin A, Lu H, Thakar J, Henriques J, et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem. 2008;283:22700–22708. doi: 10.1074/jbc.M801765200. [PMC free article] [PubMed] [Cross Ref]
67. Sutendra G, Dromparis P, Kinnaird A, Stenson TH, Haromy A, et al. Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer. Oncogene. 2013;32:1638–1650. doi: 10.1038/onc.2012.198. [PubMed] [Cross Ref]
68. Abbot EL, McCormack JG, Reynet C, Hassall DG, Buchan KW, et al. Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells. FEBS J. 2005;272:3004–3014. doi: 10.1111/j.1742-4658.2005.04713.x. [PubMed] [Cross Ref]
69. Zhang S, Hulver MW, McMillan RP, Cline MA, Gilbert ER. The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility. Nutr Metab (Lond) 2014;11:10. doi: 10.1186/1743-7075-11-10. [PMC free article] [PubMed] [Cross Ref]
70. Lee IK. The role of pyruvate dehydrogenase kinase in diabetes and obesity. Diabetes Metab J. 2014;38:181–186. doi: 10.4093/dmj.2014.38.3.181. [PMC free article] [PubMed] [Cross Ref]
71. Osthus RC, Shim H, Kim S, Li Q, Reddy R, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem. 2000;275:21797–21800. doi: 10.1074/jbc.C000023200. [PubMed] [Cross Ref]
72. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002;111:241–250. doi: 10.1016/S0092-8674(02)01014-0. [PubMed] [Cross Ref]
73. Nusse R. Wnt signaling and stem cell control. Cell Res. 2008;18:523–527. doi: 10.1038/cr.2008.47. [PubMed] [Cross Ref]
74. Niehrs C, Acebron SP. Mitotic and mitogenic Wnt signalling. EMBO J. 2012;31:2705–2713. doi: 10.1038/emboj.2012.124. [PubMed] [Cross Ref]
75. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA. 2008;105:18782–18787. doi: 10.1073/pnas.0810199105. [PubMed] [Cross Ref]
76. Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res. 2010;70:859–862. doi: 10.1158/0008-5472.CAN-09-3556. [PMC free article] [PubMed] [Cross Ref]
77. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 2007;27:7381–7393. doi: 10.1128/MCB.00440-07. [PMC free article] [PubMed] [Cross Ref]
78. Goldbeter A. Patterns of spatiotemporal organization in an allosteric enzyme model. Proc Natl Acad Sci USA. 1973;70:3255–3259. doi: 10.1073/pnas.70.11.3255. [PubMed] [Cross Ref]
79. Prigogine I, Nicolis G. Biological order, structure and instabilities. Q Rev Biophys. 1971;4:107–148. doi: 10.1017/S0033583500000615. [PubMed] [Cross Ref]
80. Mor I, Cheung EC, Vousden KH. Control of glycolysis through regulation of PFK1: old friends and recent additions. Cold Spring Harb Symp Quant Biol. 2011;76:211–216. doi: 10.1101/sqb.2011.76.010868. [PubMed] [Cross Ref]
81. Chocarro-Calvo A, Garcia-Martinez JM, Ardila-Gonzalez S, De la Vieja A, Garcia-Jimenez C. Glucose-induced beta-catenin acetylation enhances Wnt signaling in cancer. Mol Cell. 2013;49:474–486. doi: 10.1016/j.molcel.2012.11.022. [PubMed] [Cross Ref]
82. Aguilera O, Munoz-Sagastibelza M, Torrejon B, Borrero-Palacios A, Del Puerto-Nevado L, et al. Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer. Oncotarget. 2016;7:47954–47965. [PMC free article] [PubMed]
83. Khatami M. Is cancer a severe delayed hypersensitivity reaction and histamine a blueprint? Clin Transl Med. 2016;5:35. doi: 10.1186/s40169-016-0108-3. [PMC free article] [PubMed] [Cross Ref]
84. Bax BE, Bloxam DL. Energy metabolism and glycolysis in human placental trophoblast cells during differentiation. Biochim Biophys Acta. 1997;1319:283–292. doi: 10.1016/S0005-2728(96)00169-7. [PubMed] [Cross Ref]
85. Feller AC, Schneider H, Schmidt D, Parwaresch MR. Myofibroblast as a major cellular constituent of villous stroma in human placenta. Placenta. 1985;6:405–415. doi: 10.1016/S0143-4004(85)80017-5. [PubMed] [Cross Ref]
86. Chiavegato A, Bochaton-Piallat ML, D’Amore E, Sartore S, Gabbiani G. Expression of myosin heavy chain isoforms in mammary epithelial cells and in myofibroblasts from different fibrotic settings during neoplasia. Virchows Arch. 1995;426:77–86. doi: 10.1007/BF00194701. [PubMed] [Cross Ref]
87. Matsumura S, Sakurai K, Shinomiya T, Fujitani N, Key K, et al. Biochemical and immunohistochemical characterization of the isoforms of myosin and actin in human placenta. Placenta. 2011;32:347–355. doi: 10.1016/j.placenta.2011.02.008. [PubMed] [Cross Ref]
88. Lecarpentier Y, Claes V, Lecarpentier E, Guerin C, Hebert JL, et al. Ultraslow myosin molecular motors of placental contractile stem villi in humans. PLoS ONE. 2014;9:e108814. doi: 10.1371/journal.pone.0108814. [PMC free article] [PubMed] [Cross Ref]
89. Lecarpentier Y, Claes V, Hebert JL, Krokidis X, Blanc FX, et al. Statistical mechanics of the human placenta: a stationary state of a near-equilibrium system in a linear regime. PLoS ONE. 2015;10:e0142471. doi: 10.1371/journal.pone.0142471. [PMC free article] [PubMed] [Cross Ref]
90. Carthy JM, Garmaroudi FS, Luo Z, McManus BM. Wnt3a induces myofibroblast differentiation by upregulating TGF-beta signaling through SMAD2 in a beta-catenin-dependent manner. PLoS ONE. 2011;6:e19809. doi: 10.1371/journal.pone.0019809. [PMC free article] [PubMed] [Cross Ref]
91. Bernard K, Logsdon NJ, Ravi S, Xie N, Persons BP, et al. Metabolic reprogramming is required for myofibroblast contractility and differentiation. J Biol Chem. 2015;290:25427–25438. doi: 10.1074/jbc.M115.646984. [PMC free article] [PubMed] [Cross Ref]
92. Polakis P. Drugging Wnt signalling in cancer. EMBO J. 2012;31:2737–2746. doi: 10.1038/emboj.2012.126. [PubMed] [Cross Ref]
93. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012 [PMC free article] [PubMed]
94. Fuchs E. The tortoise and the hair: slow-cycling cells in the stem cell race. Cell. 2009;137:811–819. doi: 10.1016/j.cell.2009.05.002. [PMC free article] [PubMed] [Cross Ref]
95. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787–1790. doi: 10.1126/science.275.5307.1787. [PubMed] [Cross Ref]
96. Najdi R, Holcombe RF, Waterman ML. Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog. 2011;10:5. doi: 10.4103/1477-3163.78111. [PMC free article] [PubMed] [Cross Ref]
97. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell. 1999;3:799–804. doi: 10.1016/S1097-2765(01)80012-5. [PubMed] [Cross Ref]
98. Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, et al. APC-dependent suppression of colon carcinogenesis by PPAR gamma. Proc Natl Acad Sci USA. 2002;99:13771–13776. doi: 10.1073/pnas.162480299. [PubMed] [Cross Ref]
99. Brockman JA, Gupta RA, Dubois RN. Activation of PPAR gamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology. 1998;115:1049–1055. doi: 10.1016/S0016-5085(98)70072-1. [PubMed] [Cross Ref]
100. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut. 2002;50:658–664. doi: 10.1136/gut.50.5.658. [PMC free article] [PubMed] [Cross Ref]
101. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology. 2003;124:361–367. doi: 10.1053/gast.2003.50067. [PubMed] [Cross Ref]
102. Cesario RM, Stone J, Yen WC, Bissonnette RP, Lamph WW. Differentiation and growth inhibition mediated via the RXR: PPAR gamma heterodimer in colon cancer. Cancer Lett. 2006;240:225–233. doi: 10.1016/j.canlet.2005.09.010. [PubMed] [Cross Ref]
103. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 1998;4:1046–1052. doi: 10.1038/2030. [PubMed] [Cross Ref]
104. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004;5:419–429. doi: 10.1016/S1470-2045(04)01509-8. [PubMed] [Cross Ref]
105. McAlpine CA, Barak Y, Matise I, Cormier RT. Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. Int J Cancer. 2006;119:2339–2346. doi: 10.1002/ijc.22115. [PubMed] [Cross Ref]
106. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1998;1:465–470. doi: 10.1016/S1097-2765(00)80047-7. [PubMed] [Cross Ref]
107. Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis. 1999;20:1905–1911. doi: 10.1093/carcin/20.10.1905. [PubMed] [Cross Ref]
108. Pignatelli M, Cocca C, Santos A, Perez-Castillo A. Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line. Oncogene. 2003;22:5446–5450. doi: 10.1038/sj.onc.1206824. [PubMed] [Cross Ref]
109. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 1998;95:8806–8811. doi: 10.1073/pnas.95.15.8806. [PubMed] [Cross Ref]
110. Inoue K, Kawahito Y, Tsubouchi Y, Kohno M, Yoshimura R, et al. Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun. 2001;287:727–732. doi: 10.1006/bbrc.2001.5640. [PubMed] [Cross Ref]
111. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia. 1999;1:330–339. doi: 10.1038/sj.neo.7900050. [PMC free article] [PubMed] [Cross Ref]
112. Lodillinsky C, Umerez MS, Jasnis MA, Casabe A, Sandes E, et al. Bacillus Calmette-Guerin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells. Int J Mol Med. 2006;17:269–273. [PubMed]
113. Radhakrishnan SK, Gartel AL. The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines. Cell Cycle. 2005;4:582–584. doi: 10.4161/cc.4.4.1583. [PubMed] [Cross Ref]
114. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA. 2000;97:10990–10995. doi: 10.1073/pnas.180329197. [PubMed] [Cross Ref]
115. Yang FG, Zhang ZW, Xin DQ, Shi CJ, Wu JP, et al. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol Sin. 2005;26:753–761. doi: 10.1111/j.1745-7254.2005.00753.x. [PubMed] [Cross Ref]
116. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun. 2000;270:400–405. doi: 10.1006/bbrc.2000.2436. [PubMed] [Cross Ref]
117. Lee SY, Hur GY, Jung KH, Jung HC, Kim JH, et al. PPAR-gamma agonist increase gefitinib’s antitumor activity through PTEN expression. Lung Cancer. 2006;51:297–301. doi: 10.1016/j.lungcan.2005.10.010. [PubMed] [Cross Ref]
118. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, et al. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer. 2006;118:773–779. doi: 10.1002/ijc.21361. [PubMed] [Cross Ref]
119. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, et al. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer. 2000;83:1394–1400. doi: 10.1054/bjoc.2000.1457. [PMC free article] [PubMed] [Cross Ref]
120. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, et al. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. 1999;455:135–139. doi: 10.1016/S0014-5793(99)00871-6. [PubMed] [Cross Ref]
121. Lu J, Imamura K, Nomura S, Mafune K, Nakajima A, et al. Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res. 2005;65:4769–4774. doi: 10.1158/0008-5472.CAN-04-2293. [PubMed] [Cross Ref]
122. Liao SY, Zeng ZR, Leung WK, Zhou SZ, Chen B, et al. Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism, Helicobacter pylori infection and non-cardia gastric carcinoma in Chinese. Aliment Pharmacol Ther. 2006;23:289–294. doi: 10.1111/j.1365-2036.2006.02739.x. [PubMed] [Cross Ref]
123. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 1998;4:1058–1061. doi: 10.1038/2042. [PubMed] [Cross Ref]
124. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6 J-APCMin/+ mice. Nat Med. 1998;4:1053–1057. doi: 10.1038/2036. [PubMed] [Cross Ref]
125. Yang K, Fan KH, Lamprecht SA, Edelmann W, Kopelovich L, et al. Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6 J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1 ± double mutant mice. Int J Cancer. 2005;116:495–499. doi: 10.1002/ijc.21018. [PubMed] [Cross Ref]
126. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, et al. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. 2002;8:395–399. doi: 10.1097/00130404-200209000-00010. [PubMed] [Cross Ref]
127. Venkata NG, Robinson JA, Cabot PJ, Davis B, Monteith GR, et al. Mono(2-ethylhexyl)phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast. Toxicol Lett. 2006;163:224–234. doi: 10.1016/j.toxlet.2005.11.001. [PubMed] [Cross Ref]
128. Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, et al. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev. 2004;18:528–540. doi: 10.1101/gad.1167804. [PubMed] [Cross Ref]
129. Cui Y, Miyoshi K, Claudio E, Siebenlist UK, Gonzalez FJ, et al. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem. 2002;277:17830–17835. doi: 10.1074/jbc.M200186200. [PubMed] [Cross Ref]
130. Papadaki I, Mylona E, Giannopoulou I, Markaki S, Keramopoulos A, et al. PPARgamma expression in breast cancer: clinical value and correlation with ERbeta. Histopathology. 2005;46:37–42. doi: 10.1111/j.1365-2559.2005.02056.x. [PubMed] [Cross Ref]
131. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, et al. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003;79:391–397. doi: 10.1023/A:1024038127156. [PubMed] [Cross Ref]
132. Seargent JM, Yates EA, Gill JH. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol. 2004;143:933–937. doi: 10.1038/sj.bjp.0705973. [PMC free article] [PubMed] [Cross Ref]
133. Egerod FL, Nielsen HS, Iversen L, Thorup I, Storgaard T, et al. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers. 2005;10:295–309. doi: 10.1080/13547500500218682. [PubMed] [Cross Ref]
134. Yoshimura R, Matsuyama M, Segawa Y, Hase T, Mitsuhashi M, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003;104:597–602. doi: 10.1002/ijc.10980. [PubMed] [Cross Ref]
135. Lea MA, Sura M, Desbordes C. Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists. Anticancer Res. 2004;24:2765–2771. [PubMed]
136. Simons AL, Orcutt KP, Madsen JM, Scarbrough PM, Spitz DR (2012) Oxidative stress in cancer biology and therapy. In: Spitz DR, Dornfeld KJ, Krishnan J, Gius D (eds) Oxidative Stress in Applied Research and Clinical Practice. Humana Press, New York. doi:10.1007/978-1-61779-397-4
137. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24. doi: 10.1186/1476-4598-6-24. [PMC free article] [PubMed] [Cross Ref]
138. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14:381–395. doi: 10.1016/S0898-6568(01)00271-6. [PubMed] [Cross Ref]
139. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261–1274. doi: 10.1016/j.cell.2007.06.009. [PMC free article] [PubMed] [Cross Ref]
140. Karar J, Maity A. PI3 K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51. doi: 10.3389/fnmol.2011.00051. [PMC free article] [PubMed] [Cross Ref]
141. Georgescu MM. PTEN tumor suppressor network in PI3 K-Akt pathway control. Genes Cancer. 2010;1:1170–1177. doi: 10.1177/1947601911407325. [PMC free article] [PubMed] [Cross Ref]
142. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 2005;310:1504–1510. doi: 10.1126/science.1116221. [PubMed] [Cross Ref]
143. Shao J, Jung C, Liu C, Sheng H. Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem. 2005;280:26565–26572. doi: 10.1074/jbc.M413056200. [PubMed] [Cross Ref]
144. Ricchi P, Zarrilli R, Di Palma A, Acquaviva AM. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer. 2003;88:803–807. doi: 10.1038/sj.bjc.6600829. [PMC free article] [PubMed] [Cross Ref]
145. Goessling W, North TE, Loewer S, Lord AM, Lee S, et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell. 2009;136:1136–1147. doi: 10.1016/j.cell.2009.01.015. [PMC free article] [PubMed] [Cross Ref]
146. Li L, Kim HT, Nellore A, Patsoukis N, Petkova V, et al. Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/beta-catenin pathway and alters immune reconstitution after UCBT. Blood Cancer J. 2014;4:e178. doi: 10.1038/bcj.2013.75. [PMC free article] [PubMed] [Cross Ref]
147. Wong CT, Ahmad E, Li H, Crawford DA. Prostaglandin E2 alters Wnt-dependent migration and proliferation in neuroectodermal stem cells: implications for autism spectrum disorders. Cell Commun Signal. 2014;12:19. doi: 10.1186/1478-811X-12-19. [PMC free article] [PubMed] [Cross Ref]
148. Hazra S, Peebles KA, Sharma S, Mao JT, Dubinett SM. The role of PPARgamma in the cyclooxygenase pathway in lung cancer. PPAR Res. 2008;2008:790568. doi: 10.1155/2008/790568. [PMC free article] [PubMed] [Cross Ref]
149. Mendez M, LaPointe MC. PPARgamma inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes. Hypertension. 2003;42:844–850. doi: 10.1161/01.HYP.0000085332.69777.D1. [PubMed] [Cross Ref]
150. Savvidis C, Koutsilieris M. Circadian rhythm disruption in cancer biology. Mol Med. 2012;18:1249–1260. doi: 10.2119/molmed.2012.00077. [PMC free article] [PubMed] [Cross Ref]
151. Goodwin BC. Oscillatory behavior in enzymatic control processes. Adv Enzyme Regul. 1965;3:425–438. doi: 10.1016/0065-2571(65)90067-1. [PubMed] [Cross Ref]
152. Hardin PE, Hall JC, Rosbash M. Feedback of the drosophila period gene product on circadian cycling of its messenger RNA levels. Nature. 1990;343:536–540. doi: 10.1038/343536a0. [PubMed] [Cross Ref]
153. Goldbeter A. Computational approaches to cellular rhythms. Nature. 2002;420:238–245. doi: 10.1038/nature01259. [PubMed] [Cross Ref]
154. Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, et al. Role of the CLOCK protein in the mammalian circadian mechanism. Science. 1998;280:1564–1569. doi: 10.1126/science.280.5369.1564. [PubMed] [Cross Ref]
155. Hogenesch JB, Gu YZ, Jain S, Bradfield CA. The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors. Proc Natl Acad Sci USA. 1998;95:5474–5479. doi: 10.1073/pnas.95.10.5474. [PubMed] [Cross Ref]
156. Schibler U, Sassone-Corsi P. A web of circadian pacemakers. Cell. 2002;111:919–922. doi: 10.1016/S0092-8674(02)01225-4. [PubMed] [Cross Ref]
157. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002;418:935–941. doi: 10.1038/nature00965. [PubMed] [Cross Ref]
158. Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer. 2009;9:886–896. doi: 10.1038/nrc2747. [PubMed] [Cross Ref]
159. Wood PA, Yang X, Hrushesky WJ. Clock genes and cancer. Integr Cancer Ther. 2009;8:303–308. doi: 10.1177/1534735409355292. [PubMed] [Cross Ref]
160. Cao Y, Wang H, Ouyang Q, Tu Y. The free energy cost of accurate biochemical oscillations. Nat Phys. 2015;11:772–778. doi: 10.1038/nphys3412. [PMC free article] [PubMed] [Cross Ref]
161. Paschos GK, Ibrahim S, Song WL, Kunieda T, Grant G, et al. Obesity in mice with adipocyte-specific deletion of clock component Arntl. Nat Med. 2012;18:1768–1777. doi: 10.1038/nm.2979. [PMC free article] [PubMed] [Cross Ref]
162. Yang X, Wood PA, Ansell CM, Ohmori M, Oh EY, et al. Beta-catenin induces beta-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice. J Biochem. 2009;145:289–297. doi: 10.1093/jb/mvn167. [PubMed] [Cross Ref]
163. Winter SL, Bosnoyan-Collins L, Pinnaduwage D, Andrulis IL. Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors. Neoplasia. 2007;9:797–800. doi: 10.1593/neo.07595. [PMC free article] [PubMed] [Cross Ref]
164. Cao Q, Gery S, Dashti A, Yin D, Zhou Y, et al. A role for the clock gene per1 in prostate cancer. Cancer Res. 2009;69:7619–7625. doi: 10.1158/0008-5472.CAN-08-4199. [PMC free article] [PubMed] [Cross Ref]
165. Suzuki T, Sato F, Kondo J, Liu Y, Kusumi T, et al. Period is involved in the proliferation of human pancreatic MIA-PaCa2 cancer cells by TNF-alpha. Biomed Res. 2008;29:99–103. doi: 10.2220/biomedres.29.99. [PubMed] [Cross Ref]
166. Mostafaie N, Kallay E, Sauerzapf E, Bonner E, Kriwanek S, et al. Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. Mol Carcinog. 2009;48:642–647. doi: 10.1002/mc.20510. [PubMed] [Cross Ref]
167. Yang MY, Yang WC, Lin PM, Hsu JF, Hsiao HH, et al. Altered expression of circadian clock genes in human chronic myeloid leukemia. J Biol Rhythms. 2011;26:136–148. doi: 10.1177/0748730410395527. [PubMed] [Cross Ref]
168. Fujioka A, Takashima N, Shigeyoshi Y. Circadian rhythm generation in a glioma cell line. Biochem Biophys Res Commun. 2006;346:169–174. doi: 10.1016/j.bbrc.2006.05.094. [PubMed] [Cross Ref]
169. Xia HC, Niu ZF, Ma H, Cao SZ, Hao SC, et al. Deregulated expression of the Per1 and Per2 in human gliomas. Can J Neurol Sci. 2010;37:365–370. doi: 10.1017/S031716710001026X. [PubMed] [Cross Ref]
170. Chen L, Yang G. PPARs integrate the mammalian clock and energy metabolism. PPAR Res. 2014;2014:653017. [PMC free article] [PubMed]
171. Yang X, Downes M, Yu RT, Bookout AL, He W, et al. Nuclear receptor expression links the circadian clock to metabolism. Cell. 2006;126:801–810. doi: 10.1016/j.cell.2006.06.050. [PubMed] [Cross Ref]
172. Yang G, Jia Z, Aoyagi T, McClain D, Mortensen RM, et al. Systemic PPARgamma deletion impairs circadian rhythms of behavior and metabolism. PLoS ONE. 2012;7:e38117. doi: 10.1371/journal.pone.0038117. [PMC free article] [PubMed] [Cross Ref]
173. Liu C, Li S, Liu T, Borjigin J, Lin JD. Transcriptional coactivator PGC-1alpha integrates the mammalian clock and energy metabolism. Nature. 2007;447:477–481. doi: 10.1038/nature05767. [PubMed] [Cross Ref]
174. Tan Z, Luo X, Xiao L, Tang M, Bode AM, et al. The role of PGC1alpha in cancer metabolism and its therapeutic implications. Mol Cancer Ther. 2016;15:774–782. doi: 10.1158/1535-7163.MCT-15-0621. [PubMed] [Cross Ref]
175. Duez H, Staels B. Nuclear receptors linking circadian rhythms and cardiometabolic control. Arterioscler Thromb Vasc Biol. 2010;30:1529–1534. doi: 10.1161/ATVBAHA.110.209098. [PMC free article] [PubMed] [Cross Ref]

Articles from Clinical and Translational Medicine are provided here courtesy of Springer-Verlag